CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Citigroup Downgrades Evolent Health to Neutral From Buy, Adjusts Price Target to $6.75 From $5.50

Negative
AI Analysis

Summary

Citigroup downgraded Evolent Health from Buy to Neutral and adjusted its price target upward to $6.75 from $5.50.

Importance:2/10
Sentiment:
-0.30
analyst_downgradeprice_target_adjustment
Related Companies

Read the original article

Published by yahoo_finance on July 23, 2026 11:26 AM

Read Original